Rezidivrisiko bei Nierenzellkarzinom
descriptionHeading
The retrospective, multicenter study on the risk of diesease recurrence in patients with localized renal cell carcinoma is conducted with support of the Clinical Data Science Group using the infrastructure of the German Cancer Consortium's (DKTK) Clinical Communication Platform (CCP). Six university medical centers participate in this project (Essen, Dresden, Frankfurt, Freiburg, Mainz, TU Munich).
The study focuses on patients with localized renal cell carcinoma. The aim of the study is to estimate the risk of tumor recurrence in this patient group based on routine clinical data. To determine the risk of recurrence, disease-free survival and overall survival from the time of surgery to tumor recurrence or death are used. The analyses are differentiated according to the morphology of the tumor tissue, the tumor stage at diagnosis, and the outcome of the resection. Therefore, data from the tumor documentation departments of the participating sites are fed into a federated data analysis.
Prof. Dr. Viktor Grünwald (Essen) is the principal investigator, while the Frankfurt team is involved in the implementation, particularly the analyses. Other site partners are Dr. Sherif Mehralivand (Dresden), Dr. Markus Grabbert (Freiburg), Dr. Rene Mager (Mainz), and Dr. Lilly Schmalbrock (TU Munich).
